about
Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke PatientsSafety and Efficacy of YH14617 in Diabetes MellitusA Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy VolunteerPK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and RosuvastatinClinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy VolunteersA Study to Evaluate the Effect of Sarpogrelate on Blood HyperviscosityA Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706Anagre Cap. in Patients With High-Risk Essential ThrombocythemiaClinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and HyperlipidemiaA Clinical Trial of YH14642 in Patients With Chronic Periodontal DiseaseA Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy VolunteersPhase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male VolunteersStudy to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux EsophagitisFood Effect on Pharmacokinetics of YH4808 in Healthy Male SubjectsSafety and Efficacy of YHD001 in AsthmaSafety and Efficacy of YHD1023 in Erectile DysfunctionComparative Pharmacokinetics of YH14659Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male SubjectsSafety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic BronchitisSafety, Tolerability, Pharmacokinetics and Efficacy of YHD1044Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male SubjectsRosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DMEffect of Choline Alphoscerate on Cognitive Function in Alzheimer's DementiaRosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and HypercholesterolemiaHigh-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 DiabetesClinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg
P859
Q61727958-EF86358E-10A1-424B-8025-0D7C00371A69Q61956832-D729D037-508A-4E5A-A751-14761BE7B1ACQ61969930-5C26D633-2B29-4F83-8C9C-82C42B8D0789Q61974916-22707E98-19AE-46C6-BD64-6DA78352F5F3Q62062219-4B5BAC98-A3E9-42A8-A5BE-7E59DDBC34EAQ62821169-92B7F9C0-5BE8-4EB6-97C8-7ECE12B31C4CQ63011498-3B47964E-9CAB-46A7-85AF-D93336F817A9Q63012207-6869CAAD-3AB1-4C47-896A-B1CA1394BED1Q63229350-A6EF0EB8-7057-4592-A311-5E58DE21A753Q63318165-BF5CC00E-6EA4-4A1B-A465-D2A53817452FQ63318649-D25B7838-20CD-4FFE-9720-CE075784ECD8Q63319031-176994FF-C781-4C87-973C-13A82547E4A7Q63319698-D1D4BA54-1C47-4831-9C3D-B8DD83CC1362Q63320543-A66C2DF9-63C3-44BB-A663-BCD502F14F64Q63321579-A2532A1C-90E5-44D6-B27A-47FD3CADA282Q63321723-461E7DB8-82CE-4E82-B14E-E1B91A2D0E41Q63321948-0AF8E6D9-A402-4A12-95E3-D93D6998405DQ63322190-370C00BA-9F7B-47D3-8AF0-0BDD3BAFB043Q63322276-3285521E-CC60-4237-8F0D-44CE12619308Q63322437-5964126F-D91C-4965-87D1-9FEA51B272A4Q63337066-1E0794AA-D1C9-4DAF-86E1-5859B2C2A7EBQ63394376-309A8A64-4753-4AF6-8381-3D60E95FFBB0Q63400952-9BA27613-3890-4465-846A-B81B10FE3453Q63401879-ADFE4620-E855-4382-9BF3-010EC6A12AE1Q63405181-665DD54F-4713-4D36-900E-C731F96870A0Q86286086-EDDDC241-9813-482B-8CDD-11C40F6FF96AQ89153086-3670C556-B044-48B9-988A-06C2558EF619
P859
description
organisatie uit Zuid-Korea
@nl
other organization in Seoul, South Korea
@en
südkoreanische Organisation
@de
منظمة في سول، كوريا الجنوبية
@ar
name
Yuhan Corporation
@en
type
label
Yuhan Corporation
@en
prefLabel
Yuhan Corporation
@en
P131
P2427
grid.410894.0